» Articles » PMID: 11103775

Frequent Amplification of the Telomerase Reverse Transcriptase Gene in Human Tumors

Overview
Journal Cancer Res
Specialty Oncology
Date 2000 Dec 5
PMID 11103775
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of telomerase is a crucial step during cellular immortalization and malignant transformation of human cells and requires the induction of the catalytic component, human telomerase reverse transcriptase (hTERT), encoded by the hTERT gene. It is poorly understood how the hTERT gene is activated in human cancer cells. In the present study, we examined the hTERT gene copy number in human cancer cell lines and in primary tumor tissues. Amplification of the hTERT gene was observed in 8 of 26 (31%) tumor cell lines and 17 of 58 (30%) primary tumors examined (8 of 21 lung tumors, 3 of 10 cervical tumors, 5 of 19 breast carcinomas, and 1 of 8 neuroblastomas). In addition, 13 of 26 (50%) cell lines and 13 of 58 (22%) primary tumors displayed gain of hTERT gene copies with 3-4 copies/cell. The present findings imply that the hTERT locus may be a frequent target for amplification during tumorigenesis and that this genetic event probably contributes to the dysregulation of telomerase activity occurring in human tumors.

Citing Articles

A Review of Telomere Attrition in Cancer and Aging: Current Molecular Insights and Future Therapeutic Approaches.

Iskandar M, Xiao Barbero M, Jaber M, Chen R, Gomez-Guevara R, Cruz E Cancers (Basel). 2025; 17(2).

PMID: 39858038 PMC: 11764024. DOI: 10.3390/cancers17020257.


Telomere function and regulation from mouse models to human ageing and disease.

Jones-Weinert C, Mainz L, Karlseder J Nat Rev Mol Cell Biol. 2024; .

PMID: 39614014 DOI: 10.1038/s41580-024-00800-5.


Association of telomerase reverse transcriptase gene rs10069690 variant with cancer risk: an updated meta-analysis.

Zhou C, Yang Y, Shen L, Wang L, Zhang J, Wu X BMC Cancer. 2024; 24(1):1059.

PMID: 39192222 PMC: 11350973. DOI: 10.1186/s12885-024-12833-2.


Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.

Kouroukli A, Rajaram N, Bashtrykov P, Kretzmer H, Siebert R, Jeltsch A Clin Epigenetics. 2023; 15(1):183.

PMID: 37993930 PMC: 10666398. DOI: 10.1186/s13148-023-01599-2.


Assessment of MYC and TERT copy number variations in lung cancer using digital PCR.

Brik A, Wichert K, Weber D, Szafranski K, Rozynek P, Meier S BMC Res Notes. 2023; 16(1):279.

PMID: 37858127 PMC: 10585721. DOI: 10.1186/s13104-023-06566-x.